Shots:

• HER2CLIMB study involves assessing of Tukysa (tucatinib) + trastuzumab + capecitabine vs trastuzumab + capecitabine alone in 612 patients in a ratio (2:1) with LA unresectable/m-HER2+ BC prior treated with trastuzumab- pertuzumab- and T-DM1
• Updated results: 42% reduction in the risk of death- 68% reduction in the risk of CNS disease; intracranial response rate (47% vs 20%); mOS (18.1 vs 12mos.); m-CNS-PFS (9.9 vs 4.2mos); DOR (6.8 vs 3.0mos.)
• The additional analyses along with the primary analysis of HER2CLIMB- shows Tukysa is active for patients with/ out a disease that has spread to the brain. Tukysa (PO) is a TKI inhibitor of HER2 that improves OS and PFS in patients with metastatic HER2+ BC with/ out brain metastases

Click here ­to­ read full press release/ article | Ref: Seattle Genetics | Image: Seattle Genetics